FijiTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.041 (0.041–0.042) 4.7 (4.6–4.8)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.56 (0.45–0.69)
Prevalence  (includes HIV+TB) 0.97 (0.51–1.6) 110 (57–179)
Incidence  (includes HIV+TB) 0.59 (0.48–0.72) 67 (55–81)
Incidence (HIV+TB only) 0.027 (0.022–0.034) 3.1 (2.5–3.8)
         
Case detection, all forms (%) 64 (53–78)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0 (0–8.2) 0 (0–98)
MDR-TB cases among notified pulmonary
TB cases
0 (0–19) 0 (0–34)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 105   4
Pulmonary, clinically diagnosed 131   24
Extrapulmonary 109   5
       
Total new and relapse 378    
Previously treated, excluding relapses 7    
Total cases notified 385    
Among 378 new and relapse cases:
45 (12%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 12 (11%) 3 (8%) 15
Laboratory-confirmed RR-/MDR-TB cases     1
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 281 (73)
HIV-positive TB patients 11 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 11 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 11 (100)
HIV-positive people screened for TB 47  
HIV-positive people provided with IPT 1  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (77) 248
Previously treated cases, excluding relapse, registered in 2013 (64) 14
HIV-positive TB cases, all types, registered in 2013 (75) 4
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 5.6
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 6.6
% Funded domestically 59%
% Funded internationally 24%
% Unfunded 17%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-31 Data: www.who.int/tb/data